Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | GLS | O94925 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 6/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.47 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24846098 | 0.82 | NPC1 (0.47) | RAB9ANPC1TSHRGLSMEN1 | |
| SCHEMBL28952720 | 0.82 | NPC1 (0.47) | RAB9ANPC1TSHRGLSMEN1 | |
| SCHEMBL29837159 | 0.82 | NPC1 (0.47) | RAB9ANPC1TSHRGLSMEN1 | |
| SCHEMBL24846085 | 0.81 | TSHR (0.57) | RAB9ANPC1TSHRMEN1KMT2A | |
| SCHEMBL24846069 | 0.81 | RAB9A (0.67) | RAB9ANPC1TSHRGLSMEN1 | |
| SCHEMBL24846070 | 0.80 | TSHR (0.61) | TSHRMEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL24953818 | 0.79 | POLB (0.69) | MEN1KMT2AKDM4EALDH1A1LMNA | |
| SCHEMBL24846080 | 0.79 | TSHR (0.57) | RAB9ANPC1TSHRMEN1KMT2A | |
| SCHEMBL24846063 | 0.77 | TSHR (0.61) | RAB9ANPC1TSHRGLSMEN1 | |
| SCHEMBL20887237 | 0.75 | KDM4E (0.72) | RAB9ANPC1GLSMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002336-A1 | MrgprX2 Antagonists and Uses Thereof | DERMIRA, INC. | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002336-A1 | MrgprX2 Antagonists and Uses Thereof | MRGPRX2, MRGPRX1, MRGPRX4 | RAB9A 2006/4885NPC1 513/4885TSHR 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.